Met-RANTES

Drug Profile

Met-RANTES

Alternative Names: Methionylated RANTES; MetRANTES

Latest Information Update: 12 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Geneva Biomedical Research Institute; Merck Serono
  • Class Antiasthmatics; Antirheumatics; Chemokines
  • Mechanism of Action CCR1 receptor antagonists; CCR5 receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Rheumatoid arthritis

Most Recent Events

  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
  • 28 Oct 2004 Data presented at the 68th Annual Scientific Meeting of the American College of Rheumatology and the 39th Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2004) have been added to the Rheumatic Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top